Orforglipron 36 mg: In ATTAIN-1, 11% weight loss was achieved, again well above Rybelsus outcomes
The patients in this trial were admitted to a trials unit with a possible change in their sleep patterns and diet that could have caused fluctuations in ALT
Over time, researchers discovered additional benefits beyond glucose management
Because of the nutrients they contain, theyre still the best way to get the fiber your body needs to stay healthy
Because experimental studies suggest it interacts with multiple biological signalling pathways involved in tissue biology and cellular communication
Vedolizumab, a humanized IgG1 monoclonal antibody that specifically targets the 47 integrin heterodimer without affecting 41, represents the prototypical gut-selective anti-trafficking agent approved by FDA, EMA, and PMDA based on the GEMINI trials demonstrating superior efficacy over placebo for both induction and maintenance in moderate to severe UC (GEMINI 1: 47.1% clinical response and 16.9% remission at week 6
